Curcuminoid-Stevioside Complex for Influenza Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral agents for influenza virus infections have limitations such as side effects, resistance development, and low bioavailability, necessitating a new substance with superior infection inhibition and stability for both human and animal treatments.
Innovation Solution
A complex comprising a curcuminoid-based compound and stevioside, or their plant extracts, is used to create a pharmaceutical composition, food composition, virucidal quasi-drug, and feed additive, which effectively inhibits influenza virus activity and cell degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral agents (Amatadine, Rimatadine, Zanamivir, Oseltamivir) are used to treat influenza virus infection, then antiviral effects are achieved, but severe side effects occur in the nervous system and stomach
Solution Approach 1:
The patent uses natural plant-derived compounds (curcuminoid-based compounds from turmeric and stevioside from stevia) as alternative antiviral agents. These natural compounds provide the necessary antiviral effect without the severe side effects of conventional pharmaceuticals, effectively replacing harmful synthetic drugs with safer natural alternatives that can be administered repeatedly without accumulating toxic effects
Solution Approach 2:
The patent combines curcuminoid-based compounds and stevioside in a complex formulation. This composite approach synergistically enhances antiviral activity while maintaining safety. The combination of multiple natural compounds works together to achieve reliable antiviral effects without the severe side effects associated with single-conventional drugs, addressing both the effectiveness and safety concerns
2Reliability
If conventional antiviral agents are used repeatedly over 40 years, then antiviral effects are maintained, but viral tolerance and resistance develop
Solution Approach 1:
The patent changes the chemical parameters of antiviral agents by using natural plant-derived compounds with different molecular structures and mechanisms of action compared to conventional antivirals. This parameter change in the antiviral agent's composition prevents viral resistance development, as the natural compounds exhibit different interaction patterns with viral targets, making it difficult for viruses to develop tolerance through mutation
Solution Approach 2:
By using natural compounds that degrade and are excreted without long-term accumulation, the patent prevents the selection pressure that leads to resistance. The natural compounds provide effective antiviral action during treatment periods without persistent residues that could select for resistant viral strains, thereby maintaining long-term antiviral efficacy
3Reliability
If Zanamivir is used to achieve high antiviral effects, then virus proliferation is inhibited, but bioavailability is low and quick release from kidney occurs
Solution Approach 1:
The patent changes the physicochemical parameters of the antiviral agent by using curcuminoid-based compounds and stevioside, which have different absorption, distribution, metabolism, and excretion characteristics compared to Zanamivir. These natural compounds demonstrate improved bioavailability and sustained release properties, maintaining effective concentrations in the body without rapid renal elimination, thus achieving reliable antiviral effects with better pharmacokinetic profiles
4Reliability
If Oseltamivir is used to inhibit neuraminidases in influenza A and B viruses, then antiviral effects are achieved, but severe vomiting occurs
Solution Approach 1:
The patent replaces Oseltamivir with natural plant-derived compounds that provide equivalent antiviral activity without gastrointestinal side effects. These natural compounds are well-tolerated and do not induce severe vomiting, making them suitable for long-term and repeated administration to maintain antiviral protection without quality of life deterioration
Data Source
AI summary
The present invention relates to a complex comprising a compound of formula (I), or a plant extract comprising the compound or a fraction thereof; and stevioside, or a plant extract comprising the stevioside or a fraction thereof, and relates to a pharmaceutical composition for preventing or treating an influenza virus infection comprising the complex as an active ingredient. Also, the present invention relates to a food composition for preventing or improving an influenza virus infection, a virucidal quasi-drug composition, a virucidal feed additive, and a feed, which comprises the complex as an active ingredient. According to the present invention, the complex comprising a compound of formula (I), or a plant extract comprising the compound or a fraction thereof; and stevioside, or a plant extract comprising the stevioside or a fraction thereof exhibits a virucidal effect and an effect of inhibiting cell degradation against an influenza virus as well as antiviral efficacy in a specific pathogen-free (SPF) chicken, and thus can be usefully used in the prevention and treatment of an influenza virus infection.